scispace - formally typeset
M

Mariusz Kaczmarczyk

Researcher at Pomeranian Medical University

Publications -  140
Citations -  1934

Mariusz Kaczmarczyk is an academic researcher from Pomeranian Medical University. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 20, co-authored 125 publications receiving 1352 citations. Previous affiliations of Mariusz Kaczmarczyk include West Pomeranian University of Technology & University of Gdańsk.

Papers
More filters
Journal ArticleDOI

Effect of recipient sensitization (peak panel reactive antibodies) on 15-year survival after kidney transplantation.

TL;DR: The increased level of PRA in kidney recipients is a risk factor increasing mortality after the transplantation, and only peak PRA concentrations significantly correlated with increased mortality among renal transplant recipients.
Journal ArticleDOI

Two Functional TP53 Genetic Variants and Predisposition to Keloid Scarring in Caucasians.

TL;DR: The results suggest the lack of association of rs1042522 and rs17878362 TP53 polymorphisms and their haplotypes or diplotypes with the susceptibility to keloid scarring in Polish patients.
Journal ArticleDOI

An age-related decrease in factor V Leiden frequency among Polish subjects.

TL;DR: The frequency of the G1691A factor V Leiden mutation decreased with age, which indicates a shorter survival time among A1691 allele carriers in the Polish population.
Journal ArticleDOI

Clinical significance of microbiota changes under the influence of psychotropic drugs. An updated narrative review

TL;DR: The relationship between drugs and microbiota is bilateral as discussed by the authors , and proper composition of microbiota is a key to some medications used in modern medicine, thus proper composition is the key to the function of microbiota.
Journal ArticleDOI

Multiparameter flow cytometric enumeration of probiotic-containing commercial powders

TL;DR: In this article, the authors used flow cytometry (FCM) for the assessment of viability and number of freeze-dried bacteria such as: i) Lactobacillus sp., ii) Bifidobacterium sp., iii) and Lactococcus lactis in commercially available capsules.